ATNX - アテネックス （Athenex Inc.） アテネックス

The trading price of Athenex Inc. (NASDAQ:ATNX) floating lower at last check on Wednesday, May 24, closing at $0.24, -10.41% lower than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $0.221 and $0.3395. In examining the 52-week price action we see that the … Athenex Inc. (NASDAQ: ATNX) Could Fell Another -941.67% Read More »

The wave of bankruptcies comes as companies struggle to re-negotiate burdensome debtloads accumulated during the era of ultra-low interest rates. Others filing Chapter 11 petitions include KKR''s Envision Healthcare Corp, British chemical producer Venator Materials Plc, oil producer Cox Operating LLC, Kidde-Fenwal Inc and Athenex Inc.

U.S. stocks traded mixed midway through trading, with the Dow Jones trading slightly lower on Monday. The Dow traded down 0.03% to 33,290.69 while the NASDAQ rose 0.35% to 12,328.38. The S&P 500, also rose, gaining, 0.06% to 4,126.71. Check This Out: Top 5 Materials Stocks That May Collapse This Month Leading and Lagging Sectors Financials shares rose by 0.6% on Monday. Meanwhile, top gainers in the sector included Upstart Holdings, Inc. (NASDAQ: UPST ), up 11%, and Yiren Digital Ltd. (NYSE: YRD ), up 10%. In trading on Monday, utilities shares fell 1.6%. Top Headline The NY Empire State Manufacturing Index fell to -31.8 in May from 10.8 in the previous month, recording the lowest reading in four months. Analysts, meanwhile, were expecting a reading of -3.75. Equities Trading UP NeoGames S.A. (NASDAQ: NGMS ) shares shot up 112% to $27.22 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. Shares of 1847 Holdings LLC (NASDAQ: EFSH ) got a boost, shooting 53% to $0.8404 after the company reported a 27.6% increase in revenue to $15.4 million and achieved …

SoFi Technologies (NASDAQ: SOFI ) stock is on the move Monday after the financial company’s stock was hit with a downgrade Wedbush. Wedbush analysts dropped SOFI stock from its prior “neutral” rating and gave it a new “underperform” rating. For the record, the analysts’ consensus rating for SOFI shares is “hold.” That is based on 12 analysts’ opinions. To go along with that downgrade, analysts at Wedbush also dropped their price target for SOFI stock from $5 per share to $2.50 per share. That represents a potential downside of 50.2%. It’s also well below the analysts’ consensus price target of $7.23 per share. What’s Behind The Bearish SOFI Stock Rating? Wedbush analysts have raised a few concerns about the online personal finance company in a note to clients. Among them are its fee income and the possibility that the company may have to raise additional funds this year. Without more funds, SOFI may not be able to experience the growth it wants. Investors aren’t reacting well to this news with heavy trading dragging SOFI stock lower.

Greenbrook TMS (NASDAQ: GBNH ) stock is on the move Monday as the therapy center prepares to release its latest earnings report later today. Greenbrook TMS is set to release its earnings report for the first quarter of 2023 after normal trading hours today. The company intends to follow that up with a conference call at 10:00 a.m. Eastern Time on Tuesday. Company leaders will discuss the earnings report during this meeting. Investors waiting for the earnings report will want to keep a few details in mind. That includes analysts’ estimates for the period. Wall Street is expecting Greenbrook TMS to report earnings per share of -36 cents alongside revenue of $18.92 million during the quarter. Today’s GBNH Stock Movement GBNH stock started off down during pre-market trading today. The stock has been volatile in early morning trading with its recovering from those gains. However, when markets opened this morning, the stock was down 9.4%. Investors will want to keep in mind GBNH’s penny stock status.

Athenex Inc (ATNX) shares closed 4.8% lower than its previous 52 week low, giving the company a market cap of $344M. The stock is currently down 71.5% year-to-date, down 74.3% over the past 12 months, and down 74.9% over the p

Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and Germany

Athenex Inc (NASDAQ: ATNX ) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab) in advanced solid malignancies. Paclitaxel is one of the most commonly used chemotherapies. Related Link: Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast … Full story available on Benzinga.com

BUFFALO, N.Y., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of data from a Phase 1 study to assess the safety, tolerability, and activity of oral paclitaxel and encequidar (Oral Paclitaxel) in combination with pembrolizumab in patients with advanced solid malignancies. The data are being presented in a poster presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 , being held from September 16 th to September 21 st . "The encouraging interim Phase 1 data suggest promising anti-cancer activity and expected safety and tolerability observations for oral paclitaxel with pembrolizumab in lung cancer patients who had progressed on PD1/PDL1 therapies," said Dr. Rudolf Kwan, Chief Medical Officer of Athenex. "PD1/PDL1 therapies are important treatments for lung cancer but most patients eventually progress, and those patients represent an area of high unmet medical need.

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.

Athenex Inc (NASDAQ: ATNX ) has entered into licensing agreements and partnerships with Seqirus Pty Ltd , a subsidiary of CSL Limited , and AVIR Pharma Inc to commercialize tirbanibulin. Under the terms of the agreements, Seqirus will have an exclusive license to Full story available on Benzinga.com

Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada

U.S. Injectable Compounding Pharmacy Market Report 2021 added recently by CMI, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities